Precision oncology has revolutionized cancer treatment in recent years with the introduction of targeted therapies that rely on identifying specific biomarkers. Poly ADP-ribose polymerase or PARP inhibitors are a class of targeted drugs that have shown great promise in certain cancers associated with DNA repair deficiencies. However, like other targeted therapies, identifying the right patients...
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian